Aluminum Hydroxide And Magnesium Trisilicate

Introduction Overview

Generic Name

aluminum hydroxide and magnesium trisilicate

Brand Name

Gaviscon

Dosage Form

chewable tablets

Drug Class

Antacids

Pharmacokinetics

Absorption:
Gaviscon, comprising aluminum hydroxide and magnesium trisilicate, is minimally absorbed systemically when administered orally as an antacid. The primary action occurs locally in the gastrointestinal tract. The constituent components act by neutralizing gastric acid in the stomach and forming a protective barrier against acid reflux. Due to their insoluble nature, systemic absorption of aluminum and magnesium salts from Gaviscon is minimal; however, some small quantities may be absorbed depending on individual patient factors such as renal function and gastric motility. The onset of action is rapid, typically providing relief within minutes after administration.

Distribution:
Since Gaviscon components act locally within the stomach lumen and the proximal gastrointestinal tract, there is negligible systemic distribution. The aluminum and magnesium salts do not cross biological membranes significantly, and their presence in systemic circulation is minimal. Any absorbed aluminum and magnesium ions tend to be distributed into extracellular fluids and are handled primarily by renal excretion, without significant accumulation under normal dosing.

Metabolism:
Gaviscon does not undergo metabolism in the traditional hepatic sense, as it is primarily composed of inorganic salts. The drug components interact chemically with gastric acid resulting in neutralization reactions that form water and salt complexes, such as aluminum chloride and magnesium chloride. These reactions reduce gastric acidity without altering metabolic pathways. The formation of a viscous gel raft composed of aluminum hydroxide and magnesium trisilicate complexes also contributes to the drug’s local efficacy by physically preventing reflux.

Elimination:
Elimination of Gaviscon’s absorbed components occurs via the kidneys through renal excretion. Aluminum hydroxide and magnesium trisilicate are poorly absorbed, but the small amount absorbed is excreted renally, making renal function a critical consideration in elimination. Unabsorbed components remain in the gastrointestinal tract and are eliminated in the feces. Prolonged use or overdosage can lead to accumulations, especially of aluminum, in patients with impaired renal function, which may necessitate monitoring and dose adjustments.

Dosage Forms

Available Dosage Forms:
Gaviscon is commonly available as chewable tablets designed for oral administration. The specific product discussed, Gaviscon Regular Strength Tablets, requires patients to chew the tablet completely before swallowing, followed by ingestion of approximately 4 ounces of water or other suitable liquid.

Dosages for Adults and Adolescents:
Adults and adolescents are generally advised to take Gaviscon as needed for relief of heartburn, acid indigestion, sour stomach, or upset stomach associated with acid reflux. The recommended dose should not exceed 16 chewable tablets within a 24-hour period. The medication should be used exactly as prescribed or as directed on the label to ensure safety and efficacy.

Specific Patient Populations:
Caution is advised when administering Gaviscon to patients with specific conditions such as peptic ulcers, kidney disease, difficulty swallowing, or those on a low-salt diet. The product should be used with caution during pregnancy and breastfeeding; consultation with a healthcare provider is recommended before use. In patients with renal impairment, monitoring for aluminum and magnesium accumulation is essential due to altered elimination. Gaviscon is not intended for long-term use beyond two weeks unless guided by a healthcare professional.

Mechanism Of Action

Gaviscon functions primarily as an antacid by chemically neutralizing gastric hydrochloric acid through its active components aluminum hydroxide and magnesium trisilicate. When ingested, these inorganic salts react with stomach acid to form neutral salts and water, thereby raising gastric pH and reducing acidity. This neutralization aids in alleviating symptoms associated with excess gastric acid such as heartburn and indigestion.

Beyond simple acid neutralization, Gaviscon forms a viscous gel 'raft' that floats on top of the stomach contents due to its density and insolubility. This physical barrier helps prevent the reflux of acidic gastric contents into the esophagus, offering symptomatic relief from acid reflux and associated irritation. The raft mechanism also protects the esophageal mucosa from damage caused by acid reflux.

On a cellular level, reducing gastric acidity decreases the activation of pepsinogen to pepsin, an enzyme that contributes to mucosal injury when refluxed into the esophagus. By mitigating both acid and pepsin-mediated damage, Gaviscon contributes to mucosal protection. This dual chemical and mechanical mode of action differentiates it from other antacids that simply neutralize acid without raft formation.

Clinical studies have demonstrated that Gaviscon’s raft-forming property enhances symptom relief in patients with gastroesophageal reflux disease (GERD) compared to simple acid neutralizers. Furthermore, the combination of aluminum hydroxide and magnesium trisilicate balances potential adverse effects, as aluminum hydroxide can cause constipation while magnesium salts may induce diarrhea, thereby minimizing gastrointestinal side effects compared to single-agent antacids.

Pharmacological Actions

Neutralization of gastric acid via chemical reaction of aluminum hydroxide and magnesium trisilicate with hydrochloric acid.
Formation of a viscous gel raft that floats on gastric contents to prevent reflux of acid into the esophagus.
Reduction in activation of pepsinogen to pepsin, limiting mucosal damage induced by pepsin.
Rapid onset of symptomatic relief for heartburn, acid indigestion, and sour stomach.
Local action at the stomach and esophageal mucosa with minimal systemic absorption.
Balancing effect between aluminum-induced constipation and magnesium-induced diarrhea.
Protection of esophageal lining from acid-induced erosion and irritation.
Temporary symptomatic treatment of acid reflux and dyspepsia.
Does not impair gastric emptying or gut motility significantly.
Not metabolized by the liver, minimizing risk of hepatic drug interactions.
Minimal systemic toxicity with normal renal function due to poor absorption.
Acts as a protective substance for mucosal surfaces in the upper GI tract.
Utilized as adjunct symptomatic therapy in acid-related gastrointestinal disorders.
Available as chewable tablets for rapid mucosal contact and local effect.

Therapeutic Or Clinical Uses

Temporary relief of heartburn and acid indigestion associated with excess stomach acid.
Management of symptoms of gastroesophageal reflux disease (GERD) including acid reflux.
Alleviation of sour stomach and upset stomach due to hyperacidity.
Symptomatic treatment of dyspepsia and mild gastrointestinal discomfort.
Use as an adjunct therapy in disorders related to gastric hyperacidity.
Relief of gastritis-related symptoms when excess acid contributes to mucosal irritation.
Used in patients requiring immediate acid neutralization for symptomatic control.
Management of occasional acidity due to dietary or lifestyle factors.
Non-prescription treatment option for over-the-counter management of acid-related symptoms.
Supportive care during treatment of peptic ulcer disease symptoms, pending medical advice.
Temporary therapy while awaiting further diagnostic evaluation of acid-related symptoms.
Reduces esophageal irritation caused by refluxed gastric contents in mild cases.
Useful in patients with intolerance or contraindications to proton pump inhibitors or H2 blockers.
Symptomatic relief in patients with functional dyspepsia involving excess acid.

Side Or Adverse Effects

Diarrhea, typically related to magnesium content in the formulation.
Constipation, sometimes occurring due to aluminum hydroxide component.
Possible allergic reactions including hives or rash in sensitive individuals.
Rare hypersensitivity reactions with swelling of face, lips, tongue, or throat requiring emergency care.
Potential for altered electrolyte balance with prolonged or excessive use.
Rare occurrences of hypermagnesemia in patients with impaired renal function.
Risk of aluminum toxicity with long-term use in patients with compromised kidney function.
Gastrointestinal discomfort or bloating in some patients.
Rare cases of acid rebound if medication is abruptly discontinued after prolonged use.
Possible interference with absorption of other oral medications if taken simultaneously.
Indigestion related to overuse or misuse of antacid formulations.
Mild nausea reported occasionally with oral antacid preparations.
Minimal systemic adverse effects due to poor absorption, but caution in special populations.
Potential for fecal discoloration due to aluminum salts.
Headache or dizziness reported rarely but causality is uncertain.

Precautions

Consult a healthcare provider before use if patient has peptic ulcer disease.
Use with caution in patients with renal impairment to avoid aluminum and magnesium accumulation.
Avoid use in patients on sodium-restricted diets unless approved by healthcare provider.
Do not exceed recommended dosage or duration of therapy without medical advice.
Use cautiously in patients with swallowing difficulties to prevent choking.
Pregnant or breastfeeding women should seek medical advice prior to use.
Monitor for electrolyte disturbances during prolonged use, especially in elderly patients.
Separate administration times from other oral medications to prevent absorption interference.
Avoid use as a long-term treatment without physician supervision.
Patients with hypersensitivity to aluminum or magnesium salts should avoid use.
Restart therapy only under medical supervision if previously discontinued due to adverse effects.
Ensure proper chewing of tablets to optimize therapeutic effect and reduce choking risk.
Maintain hydration during use to help mitigate constipation or diarrhea adverse effects.
Discontinue if severe diarrhea or allergic reaction occurs and seek medical attention.
Review all concomitant medications with healthcare provider due to potential interactions.

Warnings

Do not use for relief of acid indigestion or heartburn for more than 2 weeks without consulting a doctor.
Seek emergency medical help if signs of allergic reaction such as difficulty breathing or swelling of face/throat occur.
Inform healthcare providers of all medical conditions and medications to avoid drug interactions.
Use caution in patients with kidney disease due to risk of magnesium or aluminum accumulation.
Risk of interference with absorption of other oral medications; stagger administration times accordingly.
Do not use if having trouble swallowing without medical advice to prevent choking hazard.
Patients should not exceed 16 chewable tablets in a 24-hour period.
Report persistent or worsening symptoms to healthcare provider promptly.
Not intended for use in children unless prescribed by a healthcare professional.
Avoid self-medication for severe or persistent gastrointestinal symptoms without evaluation.
Use in pregnancy and lactation only after consulting healthcare providers.
Avoid combining with other antacids or acid-reducing agents without medical guidance.
Store medication at room temperature away from moisture and heat to preserve efficacy.
Discontinue and consult doctor if severe gastrointestinal adverse effects develop.
Monitor for potential signs of electrolyte imbalance during extended use.

Contraindication

Hypersensitivity to aluminum hydroxide, magnesium trisilicate, or any components of Gaviscon.
Patients with known hypersensitivity or allergy to antacid compounds.
Severe renal impairment without close medical supervision due to risk of metal accumulation.
Use in patients with undiagnosed swallowing difficulties without medical assessment.
Contraindicated for long-term self-medication in cases of chronic heartburn without physician oversight.
Do not use in patients with known phosphate depletion or hypophosphatemia prior to evaluation.
Contraindicated if patient has history of severe adverse reactions to previous antacid therapy.
Avoid use in infants and children unless specifically recommended by a healthcare professional.
Use is contraindicated if patient experiences paradoxical acid reflux or unusual gastrointestinal symptoms during therapy.
Not indicated for treatment of active gastrointestinal bleeding or emergency gastrointestinal conditions.
Avoid use in patients with obstructive bowel diseases unless advised by a specialist.
Contraindicated in patients with metabolic alkalosis or hypermagnesemia without clinical assessment.
Do not use concurrently with other aluminum- or magnesium-containing medications without medical consultation.
Prolonged use contraindicated without physician monitoring to avoid systemic toxicity.
Avoid use if concomitant medications have known severe interactions with aluminum or magnesium compounds.

Drug Interactions

Gaviscon can impair absorption of multiple oral medications by altering gastric pH and binding with drugs in the GI tract.
Separate administration times of Gaviscon and other oral drugs such as antibiotics (e.g., tetracyclines, fluoroquinolones) by at least 2 hours.
May reduce efficacy of iron supplements if taken concomitantly due to chelation with aluminum and magnesium salts.
Potential interaction with digoxin leading to decreased absorption and therapeutic effect.
Concomitant use with levothyroxine may reduce absorption; separate dosing recommended.
Interaction with bisphosphonates such as alendronate, necessitating staggered dosing to avoid reduced efficacy.
Possible interaction with antiretroviral drugs requiring timing adjustments to maintain therapeutic concentration.
Concomitant administration with certain antifungals or anticonvulsants may reduce their absorption.
Gaviscon may alter urinary pH affecting renal excretion of weak acids and bases when systemically absorbed.
Interaction with ketoconazole and itraconazole due to altered gastric environment reducing drug solubility.
Combination with certain antibiotics linked to decreased bioavailability when taken simultaneously.
May interfere with the absorption of some vitamins, notably vitamin B12 and folic acid, if used long-term.
Potential to alter the effectiveness of oral contraceptives when taken concurrently, though evidence is limited.
Interactions with quinidine involve reduced absorption leading to decreased plasma levels.
Adjustments or monitoring may be required for concomitant use with warfarin or other anticoagulants due to altered GI absorption.

Preparations Of The Drug

Gaviscon Regular Strength Tablets: Chewable tablets formulated for oral administration to neutralize gastric acid.
Formulated with a combination of aluminum hydroxide and magnesium trisilicate as active ingredients.
Available as over-the-counter medication for symptomatic relief of heartburn and acid indigestion.
Packaged with dosage instructions advising chew thoroughly before swallowing and consume with water.
Non-prescription availability with recommended maximum daily dose limits and usage duration guidelines.
Manufactured with excipients designed to maintain tablet stability and patient acceptability.
Includes formulations designed to form a protective raft in the stomach for mechanical acid reflux barrier.
Available in multi-count bottles or blister packs with child-resistant safety features.
Supplied with detailed labeling outlining precautions, contraindications, and potential interactions.
Storage instructions recommend room temperature conditions away from moisture and heat exposure.
Intended for intermittent use rather than continuous long-term acid suppression therapy.
Formulations balanced to minimize gastrointestinal adverse effects such as constipation or diarrhea.
Produced under GMP (Good Manufacturing Practices) ensuring consistent potency and safety.
Available in multiple markets globally with regulatory approvals for antacid indications.
Packaging includes patient information leaflets emphasizing appropriate use and warning signs.